Early View

Review

Identification and treatment of T2-low asthma in the era of biologics

Chris Kyriakopoulos, Athena Gogali, Konstantinos Bartziokas, Konstantinos Kostikas

Please cite this article as: Kyriakopoulos C, Gogali A, Bartziokas K, et al. Identification and treatment of T2-low asthma in the era of biologics. *ERJ Open Res* 2020; in press (https://doi.org/10.1183/23120541.00309-2020).

This manuscript has recently been accepted for publication in the *ERJ Open Research*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Identification and treatment of T2-low asthma in the era of biologics

Chris Kyriakopoulos, Athena Gogali, Konstantinos Bartziokas, and Konstantinos Kostikas

Respiratory Medicine Department, University of Ioannina School of Medicine, Ioannina, Greece

Correspondence:

Dr. Konstantinos Kostikas

Respiratory Medicine Department

University of Ioannina School of Medicine, 45110 Ioannina, Greece

Tel: +30-6944780616

E-mail: ktkostikas@gmail.com
Abstract

Currently, and based on the development of relevant biologic therapies, T2-high is the most well-defined endotype of asthma. Although much progress has been made in elucidating T2-high inflammation pathways, no specific clinically applicable biomarkers for T2-low asthma have been identified. The therapeutic approach of T2-low asthma is a problem urgently needing solution, firstly because these patients have poor response to steroids, and secondly because they are not candidates for the newer targeted biologic agents. There is, thus, an unmet need for the identification of biomarkers that can help the diagnosis and endotyping of T2-low asthma.

Ongoing investigation is focusing on neutrophilic airway inflammation mediators as therapeutic targets, including IL-8, IL-17, IL-1, IL-6, IL-23, TNF-α; molecules that target to restore corticosteroid sensitivity, mainly mitogen-activated protein kinase inhibitors, tyrosine kinase inhibitors and phosphatidylinositol 3-kinase inhibitors; PDE3 inhibitors that act as bronchodilators and PDE4 inhibitors that have an anti-inflammatory effect; and airway smooth muscle mass attenuation therapies, mainly for patients with paucigranulocytic inflammation.

This manuscript aims to review the evidence for non-eosinophilic inflammation being a target for therapy in asthma, discuss current and potential future therapeutic approaches, such as novel molecules and biologic agents, and assess clinical trials of licensed drugs in the treatment of T2-low asthma.
Background

Asthma is a chronic inflammatory disorder of the airways, characterized by reversible expiratory flow limitation and bronchial hyperresponsiveness to a variety of triggers, which is an increased sensitivity of the airways resulting in bronchoconstriction. It presents with symptoms such as wheezing, shortness of breath, cough and chest tightness that vary over time and in severity [1]. This is a rough description though, as asthma is not a homogenous disease in terms of disease natural history, severity and response to treatment. It has variable clinical presentations (phenotypes) and distinct underlying pathophysiological pathways (endotypes) responsible for this heterogeneity [2]. Based on the presence of T-helper cell type 2 (Th2) driven inflammatory responses (IL-4, IL-5 and IL-13 mediated), two major asthma endotypes, Th2 and non-Th2 had been described. The recent discovery of innate lymphoid cells type-2 (ILC2) and the fact that they can release Th-2 cytokines (predominantly IL-5 and IL-13), contributing to the T2-high signature, led to the better categorization of asthma into Type-2 high (T2-high) or Type-2 and Type-2 low (T2-low) or non-Type-2 (non-T2). Currently, based on the existence of T2 biomarkers and the development of relevant biologic therapies, T2-high asthma is the most well-defined endotype [3]. T2-low asthma presents with either neutrophilic or paucigranulocytic inflammation, tends to be more resistant to inhaled corticosteroids, and it involves various asthma phenotypes, related to obesity, smoking, late onset (usually after 40 years of age) or occupational exposures [2]. There is, thus, an unmet need for the identification of biomarkers that can help the diagnosis and the endotyping of T2-low asthma. The therapeutic approach of T2-low asthma is a problem urgently needing solution for two main reasons: first, these patients have poor response to steroids, the cornerstone of asthma treatment [4], and second, they are not candidates for the newer targeted treatment with biologic agents such as anti-IgE or anti-IL-5 [5]. This review aims to discuss older as well as more recent therapeutic approaches, such as novel small molecules and biologic agents, in the treatment of T2-low asthma.

Definition of T2-low asthma
At present, a solid definition of T2-low asthma has not been established. Although some emphasis has been placed on noninvasive biomarkers for the detection of T2-high asthma (i.e. T2 cytokines, such as IL-4, IL-5, and IL-13, exhaled nitric oxide (FeNO), serum perioistin, total IgE, blood and sputum eosinophilis), the exact cut-off points for these markers are debatable [6]. Furthermore, these T2 markers may have low concordance when measured in the same patient [7, 8] and may be subject to significant variability over time and in response to asthma treatments [9]. The most important characteristic of these biomarkers is that they are characterized by high specificity, but low sensitivity, rendering them more useful in the identification of T2-high patients. In clinical practice, the most useful tool to identify T2-low asthma phenotype is the absence of any evidence of increased values in the above-mentioned biomarkers of T2-high asthma. Additionally, it seems that there is an association of T2-low asthma with obesity, smoking, pollutants, viral or bacterial infections and advanced age. In terms of pathophysiology, T2-low asthma is usually characterized by neutrophilic (NA) or the paucigranulocytic (PGA-absence of sputum eosinophilia or neutrophilia) phenotype of inflammation [10] and Th1 and/or Th17 cells seem to be the key effector cells in this setting.

Several studies have related asthma severity to airway inflammation. Sy Duong-Quy et al. has related eosinophilic inflammation to asthma management, asthma control and to predicting ICS response, through fractional exhaled nitric oxide (FeNO) measurement [11]. Kuo et al. have shown that type 2 inflammation, as reflected by FeNO, serum immunoglobulin E (IgE), and blood eosinophils plays a central role in small airways dysfunction in adults with moderate to severe persistent asthma [12]. Luis et al. demonstrated the connection between clinical activity, bronchial hyperresponsiveness, and lung function to eosinophilic, and to a lesser degree, neutrophilic inflammation [13]. In a recent study Scioscia et al. showed a positive correlation between 17β-estradiol concentrations and neutrophil levels in in the sputum of female patients with postmenopausal severe asthma, and their results confirmed the central role of neutrophils in the pathogenesis of some forms of severe late-onset asthma [14]. It is possible that increased airway remodelling is an important future risk factor for asthma, inducing further decline in pulmonary function, increased BHR, and exacerbation rate [15].
Neutrophilic phenotype

The percentage of neutrophils in the sputum of healthy controls ranges from 0-64% [16, 17], the aetiology of which may be shear stress in the mucosa during the induction process, the influence of specific resident microbiota or prior exposures to environmental agents. Airway neutrophilia may be associated with pollution [18], smoking [19], workplace agents [20], acute infections [21], chronic airway infections (e.g. in bronchiectasis) [22] or with an altered airway microbiome [23]. NA is common in smokers with asthma [19], in obese asthmatics [24] and occupational asthma [25, 26]. The NA phenotype is characterized by a neutrophilic proportion of ≥64% in induced sputum [27, 28], although different cut off values have been used in different studies ranging from 40-76% [29]. It is uncertain which cut off value correlates with activated neutrophils promoting the pathogenic process [30], nevertheless, sputum neutrophil counts have been associated with disease severity [31]. It is prudent to mention that sputum total cell count, >15 x 10⁶/g with a neutrophil percentage greater than 64% is a strong indication of lower airway tract infection [32].

The NA phenotype accounts for 5-22% of the asthmatic patients [33] often related to more severe disease with worse pulmonary function and poor asthma control [13]. Patients with NA are less responsive to ICS [34]; however, it is unclear if this corticosteroid insensitivity is related to the presence of neutrophils or if it is induced by the mechanisms underlying neutrophil recruitment [35].

Although blood eosinophils correlate with sputum eosinophilia, this is not applicable in NA in which blood neutrophilia cannot predict airway neutrophilia [30]. There are several candidate biomarkers to define NA, however, apart from the differential sputum cell counts; they are not applicable in clinical daily practice. Several cytokines are associated with neutrophilic airway inflammation. IL-6 is a pleiotropic cytokine produced by various cell types in response to a wide range of inflammatory stimuli. It is considered an indicator of metabolic dysfunction as well as asthma severity and has been identified as a potential candidate biomarker in a study with obese asthmatic patients [36]. Increased levels of IL-8, which is known to activate neutrophils, have been observed in patients with NA [37] and were linked to sputum neutrophil counts [38]. Other important biomarkers of neutrophil
induction are myeloperoxidase and neutrophil elastase which can be discovered in induced sputum samples [39]. TNF-α [40], IL-23 [41] and IL-17 [42] are also related to neutrophilic inflammation in asthma. Maes et al. have suggested that certain micro-RNAs in sputum might be able to accurately identify neutrophilic airway inflammation, but most clinicians are unable to obtain satisfactory sputum samples from these patients [43]. Transcriptomic analysis of airway samples in severe neutrophilic asthma found a strong upregulation of mucins, IL-17-inducible chemokines (CXCL1, CXCL2, CXCL3, and CSF-3) and the neutrophil chemoattractants CXCL8 (IL-8), CCL3 and Galectin-3 (LGALS3) [44]. Signatures of antibacterial responses including CD14, JUN and TLR2, implicate airway bacteria in driving the neutrophilia [45]. NA is associated with airway colonisation by bacteria including Haemophilus influenza [46] and Moraxella catarrhalis [47], which might induce Th17 responses [48]. Neutrophilic asthma is also associated with upregulation of oxidative stress responses and matrix metalloproteases [49], including MMP-9, a type IV collagenase involved with CXCL8-induced neutrophilia [50]. MMPs are increased in airway samples from asthmatic smokers and in severe neutrophilic asthma and are implicated in tissue remodelling [51].

Paucigranulocytic phenotype

Asthmatic patients with both neutrophil levels <64% and eosinophil levels <2% are classified as having PGA [29]. The prevalence of this phenotype in asthmatic patients ranges from 17%-48% in different studies [30, 37]. Although little is known about the PGA phenotype, in the majority of patients with PGA the absence of inflammatory cells is usually related to appropriate anti-inflammatory treatment that achieves adequate asthma control [30]. Even though PGA is related to better lung function, a substantial proportion of patients with PGA (21.7%) is characterized as having severe refractory asthma, and 14.8% of patients with PGA has an Asthma Control Test score of less than 19, suggesting that only this subpopulation of PGA is not well controlled despite the absence of inflammatory cells in their sputum [38]. Surprisingly, in a cohort, patients with PGA with severe refractory asthma presented with higher levels of FeNO and sputum IL-13 and IL-8 compared with those with mild/moderate asthma [37, 41]. Animal models
demonstrate that processes stimulating airway hyperresponsiveness and airway smooth muscle thickening occur independently from inflammation and are a consequence of a loss of negative homeostatic processes, advancing eventually to the pathogenesis of asthma in PGA phenotype [52].

The main clinical and pathophysiological characteristics that can help distinguish T2-low from T2-high asthma are shown in Table 1, while possible pathogenetic pathways; current drug targets and those in the development pipeline are shown in Figure 1.
Table 1. Characteristics of T2-low vs. T2-high asthma

| Differential Diagnostic Characteristics of T2-asthma | T2-low asthma | T2-high asthma |
|------------------------------------------------------|---------------|----------------|
| Onset                                                | Late          | Early          |
| Symptoms                                             | Mostly significant | May be significant |
| Obesity                                              | Often present | May be present |
| Smoking                                              | Often present | May be present |
| Response to inhaled corticosteroids                   | Often poor    | Usually good   |
| Severity of asthma                                   | Often difficult to treat | Mild to severe |
| Asthma Control                                       | Often poor    | Variable       |
| Sputum eosinophils                                   | Absent        | Normal or high levels |
| Sputum neutrophils                                   | Frequently present | May be present |
| Exhaled nitric oxide                                 | Usually normal | Elevated or normal |
| Airways                                              | Often present | May be present |

Current therapeutic options
Presently, there are no specific therapeutic interventions for patients with PGA. A very crucial and low cost, but often overlooked intervention that may dramatically improve asthma control also in patients with NA, is smoking cessation and avoidance of exposure to environmental/occupational pollutant agents. In neutrophilic asthmatic smokers, smoking cessation and avoidance of second-hand smoke resulted in the reduction of neutrophilic inflammation and improved asthma control and lung function [53].

Other treatment approaches currently available for T2-low asthma, address non-inflammatory pathways possibly involved in its pathogenesis. Tiotropium has been recently included as a new add-on treatment for GINA Steps 4 and 5 in patients aged ≥18 years with a history of exacerbations. Its clinical efficacy has been demonstrated in patients with fixed airway obstruction, an asthma phenotype usually associated with neutrophilic airway inflammation [54] and in patients with low sputum eosinophils (and possibly T2-low asthma) [55].

Macrolides are often administered in refractory NA, although these antibiotics promote an enhanced risk of adverse events and promote bacterial resistance [56]. Macrolides exhibit their beneficial effects in NA with three mechanisms: 1) they exert antibacterial [57] and antiviral actions [58]; 2) they demonstrate immunomodulatory effects and anti-inflammatory activity through inhibition of transcription factors such as NFκB, reduction of activation and migration of neutrophils [59], revitalization of corticosteroid sensitivity by inhibiting the Phosphatidylinositol 3-kinase (PI3K) pathway and restoring histone deacetylase 2 (HDAC2) [60] and by attenuating TNF-α and IL-17 immune responses [59]; and 3) they display prokinetic properties, thus diminishing the pernicious consequences of reflux and aspiration events [61]. Although not explicitly highlighted, macrolides reduce the sequence of reflux effects that include: micro and macro aspiration of gastric contents; bronchoconstriction mediated by vagal reflexes [62] and neurogenic inflammation in the lung [63]. Erythromycin has been shown to promote gastric and small bowel motility [64], increase lower oesophageal sphincter pressure [65] and affect gallbladder function [66]. Azithromycin also exhibits action as a motilin receptor agonist [67] and enhances gastric motility in healthy subjects [68]. In patients with impaired gastrointestinal
motility, azithromycin has shown comparable positive effects on gastric and duodenal motility to erythromycin [67]. In one study which included smoking asthmatics, the use of azithromycin did not induce amelioration of asthma control or lung function [69]. In other reports, azithromycin significantly improved asthma exacerbations and quality of life in both eosinophilic and non-eosinophilic asthma [70, 71]. Moreover, the use of clarithromycin in patients with NA resulted in the reduction of neutrophilic inflammation followed by improvement in asthma control [72]. In a large randomized, double-blind study in moderate-to-severe asthma in Australia (AMAZES), azithromycin reduced exacerbations and improved Asthma Quality of Life Questionnaire (AQLQ) scores [71]. Moreover, current ERS/ATS severe asthma guidelines recommend the use of azithromycin in severe asthma that does not respond to treatment [73].

Bronchial thermoplasty (BT) could be a possible therapeutic approach, but its long term effectiveness or adverse events have not been fully assessed in PGA [74]. BT administers targeted thermal energy to the airway wall ablating airway smooth muscle (ASM) cells with a subsequent decrease in the ASM mass [75] while it has been verified that thermoplasty also regulates mucosal inflammatory responses and collagen deposition [76]. This intervention has been observed to reduce asthma exacerbations and to improve lung function and health-related quality of life. Moreover, macrolides may be an effective option in PGA since the potential effects of azithromycin have been observed irrespective of the underlying airway inflammation [70].

The use of statins in clinical trials demonstrated alterations in several inflammatory markers but failed to show improvement in asthma control or lung function [77].

Given the high prevalence of obesity in patients with T2-low asthma, weight reduction along with exercise and dietary modification should be included in the therapeutic plan of those patients. Several clinical studies have shown that weight loss in obese patients not only improves asthma symptoms but also contributes to a reduction in doses of rescue medication. It also reduces the risk for severe asthma exacerbations and improves asthma-related quality of life, perhaps through improvements in lung function [78–80].
Future therapeutic targets

Although no specific treatments have been made available so far, according to the pathophysiology of T2-low asthma, some potential targets for therapeutic interventions are summarized below [81]. An overview of the major biologic approaches currently in development for type 2 low asthma management is shown in Table 2.

1) Cysteine X cysteine chemokine receptor 2 (CXCR2)/IL-8

IL-8 is a potent chemoattractant that regulates activation and migration of neutrophils to the site of inflammation through the high-affinity CXCR2 receptor. Increased levels of IL-8 in sputum often precede asthma exacerbations in severe asthmatics and coincide with the development of late-phase airflow obstruction in patients with atopy [82]. IL-8 is also elevated in the serum of those patients, but its role as a biomarker demonstrating disease activity remains disputable. CXCR2 is a common chemokine receptor, which is expressed on the surface of neutrophils. The tripeptide PGP, which is generated from extracellular matrix proteins through the action of matrix metalloproteinases, is also a neutrophil chemoattractant (matrikine) that activates CXCR2 [83]. These chemokines also attract circulating monocytes, which differentiate within the lung to macrophages that are thought to guide neutrophilic inflammation [84]. This implicates that blocking CXCR2 could be a tempting therapeutic approach to the treatment of neutrophilic inflammation since small molecule inhibitors to these G-protein receptors have now been developed.

In a phase 2 study of patients with moderate to severe asthma with high neutrophils count at baseline (>40%), CXCR2 antagonist SCH527123/Navarixin demonstrated a significant reduction in sputum neutrophils by 36.3% compared to a 6.7% increase in the placebo group (p=0.03), but no significant improvement of asthma control was established and no change to FEV1 was proved [85, 86]. In a subsequent randomized clinical trial, using a CXCR2 antagonist (AZD5069) as add on therapy for patients with severe asthma 45 mg BID (n=161) for up 12 months resulted in a sustained ~25%, reversible on discontinuation of treatment and reduction in blood neutrophils. In severe asthmatics, 5, 15 or 45 mg BID for 6
months did not reduce the rate of exacerbations nor improved FEV1 or total asthma symptom score. A statistically significant reduction of sputum neutrophils by 69% was found in bronchiectasis patients after 80 mg BID for 4 weeks. There was no consistent increase in the rate of infections [86]. Another phase 1 clinical trial treatment of AZD8309, a CXCR2 antagonist, demonstrated a mean 77% reduction in total sputum cells (p < 0.001) and 79% reduction in sputum neutrophils (p < 0.05) compared with placebo after LPS challenge. There was also a reduction in neutrophil elastase activity (p < 0.05) and CXCL1 (p < 0.05) and trends for a reduction in sputum macrophages (47%), leukotriene B₄ (39%) and CXCL8 (52%). The clinical trial was discontinued for asthma [87]. Overall, although CXCR2 antagonists seemed to be promising molecules as an add-on therapy for severe uncontrolled NA, they were not able to improve clinical outcomes and exacerbation rates [85–87].

2) Interleukin 17

IL-17A and IL-17F are produced by Th17 cells and trigger the production of IL-8 and CXCL1 from epithelial cells. Moreover, they are neutrophil chemoattractants [88], while Th1 cells are connected to neutrophilic inflammation, by producing INF-γ and TNF-α. Neutrophilic inflammation generated by this pathway leads to airway injury and remodelling, hyperplasia and hypersecretion of the mucous gland and corticosteroid insensitivity [77]. It has been recorded that severe NA is related to higher levels of Th17 cytokines primarily CXCL1, CXCL10, CCl-2, IL-6 and IL-8 in comparison to other inflammatory endotypes [89]. In patients with asthma, elevated levels of IL-17A and IL-17F are found in BAL and airway tissue biopsies and positively correlate with the level of disease severity and neutrophil inflammation [90]. Furthermore, IL-17A acts on airway smooth muscle cells and mediates airway hyperresponsiveness. IL-17A and IL17F bind to receptor complexes with IL-17RA serving as the common subunit. Nevertheless, a recent study with mice models suggested that IL-17F, rather than IL-17A, underlies airway inflammation in steroid-insensitive asthma [91].

Secukinumab, an IL-17A blocker, administration in healthy volunteers who evolved acute neutrophilic airway inflammation following an ozone challenge did not demonstrate a significant change in the total number of sputum neutrophils
from baseline. In a subsequent phase 2 study of AIN457 (secukinumab) in patients with uncontrolled asthma, there was no difference in ACQ score leading to its termination [92]. Brodalumab is a human monoclonal antibody that is blocking the activity of IL-17A, IL-17B, and IL-25 through binding to IL-17RA. In a randomized controlled trial recruiting patients with uncontrolled, moderate to severe asthma on inhaled corticosteroids, brodalumab failed to show a change in ACQ score, asthma symptoms or lung function in the overall study population. However, it did show a trend towards improvement in ACQ score in a small subgroup of patients with high bronchodilator reversibility [93]. However, this drug led to significant mental health issues in clinical trials, thus resulting in discontinuation of further development for asthma. Another formulation of secukinumab (CJM112), an anti-IL17A antibody, is now in phase 2 randomized clinical trial for patients with inadequately controlled moderate to severe asthma with low IgE and low circulating eosinophil levels, but no results have been announced yet [94].

3) Phosphodiesterases (PDE)

Most PDE isoenzymes are expressed in lung tissue, including PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE8, and PDE9; however, PDE3 and PDE4 have been the primary targets for drug therapy. The PDE4 isoenzyme is found in most inflammatory and immune cells, including T-cells, eosinophils, neutrophils, B-cells, monocytes, macrophages, and dendritic cells. In several preclinical studies, PDE4 inhibitors have been shown to suppress bronchial hyper-responsiveness, eosinophil infiltration, and production of histamine, leukotrienes, and cytokines, however with significant side effects when administered orally. PDE3 inhibitors act as bronchodilators, while PDE4 inhibitors have an anti-inflammatory effect [95]. PRL-554, an inhaled phosphodiesterase 3/4 inhibitor is now in a phase 1 trial for severe asthma. It is an analogue of trequinsin and, like trequinsin, is a highly selective inhibitor of the phosphodiesterase enzyme, PDE3. Indeed, it is >3000-times more potent against PDE3 than against PDE4. Ensifentrine (RPL554), a nebulized PDE3/4 inhibitor, demonstrated a significant dose-dependent bronchodilator response in asthma patients [77, 96, 97]. CHF6001, an inhaled PDE4 inhibitor, was evaluated in a phase 2 trial; the drug was safe and well-
tolerated at daily doses up to 4800µg for 14 days in healthy volunteers. No results have been announced yet about drug efficacy [98].

4) Tumour necrosis factor-alpha (TNF-a)

TNF-a is secreted by lymphocytes, mast cells, and macrophages and promotes bronchial hyperresponsiveness and sputum neutrophilia thus was considered as an attractive target for severe asthma [99]. Etanercept (anti TNF-a) showed short term and modest clinical efficacy for severe and mild asthma respectively [100]. Mild reduction in the number of exacerbations and improvement in wheezing was observed in patients with moderate uncontrolled asthma, who were under monotherapy with inhaled corticosteroids (ICS), after administration of infliximab or adalimumab [101]. Golimumab lowered risk of asthma exacerbations, nevertheless, its trial on severe persistent asthma ended at phase II due to incidences of malignancies and infections such as pneumonia [99]. Given the possible beneficial role of TNF-a in severe NA, future studies may need to evaluate the long-term risk-benefit profile of these agents in such patients.

5) Interleukin 1 (IL-1)

IL-1β and IL-1 receptor antagonist (IL-1 RA) genes have both been associated with asthma risk [102]. In humans, IL-1β is increased in bronchoalveolar lavage (BAL) fluid and sputum of asthmatics compared to normal volunteers [103], with airway macrophages from asthmatics also having increased expression of IL-1β [104]. IL-1β is also increased in BAL fluid from persons with symptomatic asthma vs. those with asymptomatic asthma [105], and there is an increased expression of this cytokine in the airways’ epithelium of asthmatics [105]. IL-1β also appears to be involved in the recruitment of airway neutrophils by LPS in rat models [106] and is upregulated in the airway after LPS inhalation challenge in humans [107]. Canakinumab, a fully human immunoglobulin IgG1k monoclonal antibody against IL-1β was originally developed as a potential treatment for asthma but is no longer listed for that indication [108]. A study of anakinra, an IL-1β antagonist, in NA demonstrated a significant reduction of airway neutrophilia compared to placebo; subjects tolerated the treatment well, without an increased frequency of infections that were attributable to anakinra [109].
7) **Interleukin 6 (IL-6)**

IL-6 in sputum is associated with a lower FEV₁ in patients with mixed eosinophilic-neutrophilic bronchitis [110]. In mice, allergen exposure increased lung IL-6, and IL-6 was produced by dendritic cells and alveolar macrophages. Loss of function of IL-6 signaling abrogated elevations of eosinophil and neutrophil recruiting cytokines/chemokines and allergen-induced airway inflammation in mice. The association of pleiotropic cellular airway inflammation with IL-6 using human and animal data suggests that exacerbations of asthma, particularly those with a combined eosinophilic and neutrophilic bronchitis, may respond to therapies targeting the IL-6 pathway [111]. Sirukumab, an IL-6 antagonist for patients having uncontrolled severe asthma despite the use of high dose ICS in combination with LABA is now in a phase 2a trial [112].

8) **Interleukins 22 and 23 (IL-22, IL-23)**

Currently, one phase 2 ongoing clinical trial for anti-IL-23 monoclonal antibody (risankizumab) attempts to investigate the efficacy and safety profile of this agent in T2-low severe asthmatic patients (NCT02443298). There are no ongoing studies on IL-22 targeted therapy in asthma.

9) **Protein Kinases**

Several p38 mitogen-activated protein kinases (MAPK) inhibitors have shown to restore corticosteroid sensitivity in peripheral blood mononuclear cells from patients with severe asthma [113]. A phase 2 study of PF03715455 was conducted and was terminated due to business reasons, without any safety or efficacy concerns [114]. A post hoc analysis of a 6-month clinical trial with losmapimod (GW856553) in COPD, but not in asthma, reported a reduction in exacerbations in a subgroup of patients with a blood eosinophil count ≤2%, which may suggest a preferentially beneficial effect of p38 MAPK inhibitors in non-eosinophilic inflammation [115]. AZD7624, an inhaled p38α and p38β inhibitor, in COPD, significantly reduced additional inflammatory biomarkers from sputum (IL-6, IL-8, and MIP-1β) and blood (neutrophil percentage, IL-6, MIP-1β, and CRP), but demonstrated no benefit concerning the reduction of exacerbations [116].
Inhibition of the stem cell factor/c-kit receptor pathway leads to a significant decrease of the mast cell population, histamine levels, interleukin-4 production and airway hyper-responsiveness. Growth factors such as platelet-derived growth factor (PDGF) contribute to bronchial remodelling, a characteristic of severe asthma [117]. Masitinib and imatinib are tyrosine kinase inhibitors, targeting stem cell factor receptor/c-kit and PDGF receptor. A phase 2a study of masitinib in severe, uncontrolled, corticosteroid-dependent asthmatics was conducted, showing no significant difference to the corticosteroid weaning process. Contrary to that, a significant improvement in asthma control was observed [118].

Phosphatidylinositol 3-kinase (PI3K) and Janus-activated kinases (JAK) modulate lymphocyte activation. JAK and PI3K inhibitors reduced the cytokine level through direct effects on T-cell activation in both asthma and healthy BAL cells. Nemiralisib (GSK2269557), a once-daily inhaled PI3Kδ inhibitor underwent a Phase 2 clinical trial for patients with severe, uncontrolled asthma. It exhibited a significant reduction in sputum IL-5, IL-13, IL-6, and IL-8 level; however with no discernible difference in trough FEV, and ACT score [119]. PI3K δ and γ isoforms are involved in inflammatory cell recruitment and activation and dual PI3Kδ/γ inhibitors, such as TG100-115 and IPI145 reduces airway inflammation induced by allergen or cigarette smoke in murine models [120, 121] and restored corticosteroid sensitivity in the smoke model [121]. A phase 2 study of RV1729, an inhaled PI3Kγ/δ inhibitor, demonstrated attenuation of airway inflammation, promotion of bronchodilation and reversal of β2 adrenoreceptor tachyphylaxis [122]. Both IPI-145 (duvelisib) and RV-1729 are PI3Kδ/PI3Kγ combination inhibitors that are being developed for clinical use [120, 121]. Furthermore, the combination of dexamethasone with either a JAK or PI3Kδ inhibitor showed an additive anti-inflammatory effect [123]. Recently, an inhaled inhibitor of Janus kinase 1 (JAK1) and intravenous administration of human mesenchymal stem cells attenuated neutrophilic inflammation in an experimental murine of allergic asthma [124]. Overall, the inhibition of PI3K blunts mucus production, prevents mast cell degranulation, deters immune cell recruitment and facilitates bronchodilation, all of which are potentially beneficial in asthma [125], but these need to be proven in future clinical trials.
Conclusions

Treating T2-low asthma is a therapeutic challenge, mainly because its mechanisms are not fully understood. Although much progress has been made in elucidating T2-high inflammation pathways, no specific biomarkers for T2-low asthma have been identified. Neutrophilic airway inflammation mediators targets, including IL-8, IL-17, IL-1, IL-6, IL-23, TNF-a or airway smooth muscle mass attenuation therapies (for paucigranulocytic inflammation) are under investigation. Failed previous attempts with some of the agents targeting these mechanisms may have been due to the poor characterization of severe T2-low asthma. Further studies are necessary to accurately characterize T2-low pathogenetic processes to assess novel evidence-based treatments.

Abbreviations

Airway smooth muscle: ASM; Asthma Control Questionnaire: ACQ; Asthma Control Test: ACT; bronchial hyperresponsiveness: BHR; bronchial thermoplasty: BT; bronchoalveolar lavage: BAL; cysteine X cysteine chemokine receptor 2: CXCR2; fractional exhaled nitric oxide: FeNO; histone deacetylase 2: HDAC2; Innate lymphoid cells: ILCs; inhaled corticosteroids: ICS; janus-activated kinases: JAK; long-acting beta-agonist: LABA; Interleukin: IL; Galectin-3:LGALS3; macrophage inflammatory protein-1β: MIP-1β; mitogen-activated protein kinases: MARK; neutrophilic asthma: NA; nuclear factor kappa-light-chain-enhancer of activated B cells: NF-κB; paucigranulocytic asthma: PGA; phosphatidylinositol 3-kinase: PI3K; platelet-derived growth factor: PDGF; and tumour necrosis factor-a: TNF-a.
Table 2. Overview of the major biologic approaches currently in development for type 2 low asthma management

| Target patient population | Studied biomarker | Biologic (drug name) | Drug type | Sponsor | Main effects | Ref. |
|---------------------------|------------------|----------------------|-----------|---------|--------------|------|
| Add-on therapy in severe uncontrolled neutrophilic asthma | IL-8 | SCH527123/Navarixin | CXCR2 antagonist | AstraZeneca | Reduction in sputum neutrophils and in blood neutrophils No improvement in clinical outcomes and exacerbation rates | [85–87] |
| Add-on therapy in uncontrolled moderate to severe asthma | IL-17 | Brodalumab | Humananti-IL-17receptor | LEO Pharma A/S | Did not improve ACQ score, lung function or asthma symptoms | [93] |
| Add-on therapy in severe uncontrolled neutrophilic asthma | PDE4 | PRL-554 CHF6001 (inhaled) | Dual phosphodiesterase PDE3 and PDE4 inhibitors | Verona Pharma ChiesiFar maceutici S.p.A | Bronchodilatatory and anti-inflammatory effect | [96] [97] |
| Severe and mild asthma Severe, refractory, or steroid-resistant asthma | TNF-α | Etanercept Golimumab | Human monoclonal antibody against TNF-α | Pfizer Janssen Biologics B.V. | Treatment was associated with substantial adverse reactionssuch as infections and malignancies | [100] [99] |
| Add-on therapy in | IL-1 | Anakinra | Human IL-1 receptor | SwedishOrphanBiovit | Reduced neutrophilic airway | [109] |
| Severe uncontrolled neutrophilic asthma | Severe neutrophilic asthma | Severe uncontrolled asthma | Severe neutrophilic asthma |
|----------------------------------------|---------------------------|---------------------------|---------------------------|
| Antagonist (IL-1 Ra)                    | Losmapimod               | Nemiralisib               | Glaxo SmithKline          |
| Rem AB                                  | AzD7624                   | IPI-145                   | AstraZeneca               |
| Inflammation and sputum levels of      | Masitinib, imatinib       | RV-1729 (duvelisib)       | AB-Science, Novartis      |
| IL-1b, IL-6 and IL-8                    |                           |                           |                           |
| Reduced exacerbations                   |                           |                           | Reduced inflammatory      |
| Reduced inflammatory biomarkers from    |                           |                           | biomarkers from blood     |
| blood (IL-6, neutrophil percentage, and |                           |                           | IL-6, and IL-8)           |
| CRP) and sputum (IL-6, and IL-8)        |                           |                           | Improved asthma control   |
| Attenuation of airway inflammation,    |                           |                           |                           |
| promotion of bronchodilation and        |                           |                           |                           |
| reversal of β2 adrenoreceptor           |                           |                           |                           |
| tachyphylaxis                           |                           |                           |                           |

[115] [116] [118] [119] [120] [21] [122]
References

1. Global Initiative For Asthma. 2019 Pocket Guide for Asthma Management: For Adults and Children Over 5
   Years. https://books.google.com/books/about/2019_Pocket_Guide_for_Asthma_Management.html. Date last updated: Apr 10 2019. Date last accessed: May 10 2020.

2. Kuruvilla ME, Lee FE-H, Lee GB. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. *Clin. Rev. Allergy Immunol.* 2019; 56: 219–233.

3. van Rijt L, von Richthofen H, van Ree R. Type 2 innate lymphoid cells: at the cross-roads in allergic asthma. *Semin. Immunopathol.* 2016; 38: 483–496.

4. Gaga M, Zervas E, Samitas K, Bel EH. Severe Asthma in Adults. *Clinics in Chest Medicine* 2012; 33: 571–583.

5. Holguin F, Cardet JC, Chung KF et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. *Eur. Respir. J.* 2020; 55.

6. Exploring the Utility of Noninvasive Type 2 Inflammatory Markers for Prediction of Severe Asthma Exacerbations in Children and Adolescents. *J. Allergy Clin. Immunol. Pract.* Elsevier; 2019; 7: 2624–2633.e2.

7. Hastie AT, Moore WC, Li H, Rector BM, Ortega VE, Pascual RM, Peters SP, Meyers DA, Bleecker ER, National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. *J. Allergy Clin. Immunol.* 2013; 132: 72–80.

8. Haughney J, Morice A, Blyth KG, Lee AJ, Coutts A, McKnight E, Pavord I. A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels. *Respir. Med.* 2018; 134: 117–123.
9. Mathur SK, Fichtinger PS, Evans MD, Schwantes EA, Jarjour NN. Variability of blood eosinophil count as an asthma biomarker. *Ann. Allergy Asthma Immunol.* 2016; 117: 551–553.

10. Papaioannou AI, Diamant Z, Bakakos P, Loukides S. Towards precision medicine in severe asthma: Treatment algorithms based on treatable traits. *Respir. Med.* 2018; 142: 15–22.

11. Kuo CR, Jabbal S, Lipworth B. Is small airways dysfunction related to asthma control and type 2 inflammation? *Ann. Allergy Asthma Immunol.* 2018; p. 631–632.

12. Duong-Quy S. Clinical Utility Of The Exhaled Nitric Oxide (NO) Measurement With Portable Devices In The Management Of Allergic Airway Inflammation And Asthma. *J. Asthma Allergy* 2019; 12: 331–341.

13. Louis R, Lau LCK, Bron AO, Roldaan AC, Radermecker M, Djukanović R. The Relationship between Airways Inflammation and Asthma Severity. American Journal of Respiratory and Critical Care Medicine 2000. p. 9–16.

14. Wardzyńska A, Pawełczyk M, Rywaniak J, Kurowski M, Makowska JS, Kowalski ML. Circulating MicroRNAs and T-Cell Cytokine Expression Are Associated With the Characteristics of Asthma Exacerbation. Allergy, Asthma & Immunology Research 2020; p.125Available from: http://dx.doi.org/10.4168/aair.2020.12.1.125.

15. Scioscia G, Carpagnano GE, Lacedonia D, Soccio P, Quarato CMI, Trabace L, Fusó P, Barbaro MPF. The Role of Airways 17β-Estradiol as a Biomarker of Severity in Postmenopausal Asthma: A Pilot Study. *J. Clin. Med. Res.*

16. Reid, Reid. Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD. 2010. p. 327.

17. Pirogov AB, Prikhod’ko AG, Perelman YM, Zinovyev SV, Yu. Afanasyeva E, Kolosov VP. Inflammatory Pattern of the Bronchial Mucosa in Patients with Asthma with Airway Hyperresponsiveness to Hypoosmotic Stimulus. *Bulletin of*
18. Alexis NE, Carlsten C. Interplay of air pollution and asthma immunopathogenesis: A focused review of diesel exhaust and ozone. International Immunopharmacology 2014. p. 347–355

19. Shimoda T, Obase Y, Kishikawa R, Iwanaga T. Influence of cigarette smoking on airway inflammation and inhaled corticosteroid treatment in patients with asthma. Allergy and Asthma Proceedings 2016. p. 50–58.

20. Tarlo SM, Lemiere C. Occupational Asthma. New England Journal of Medicine 2014. p. 640–649.

21. Yang X, Jiang Y, Wang C. Does IL-17 Respond to the Disordered Lung Microbiome and Contribute to the Neutrophilic Phenotype in Asthma? Mediators of Inflammation 2016; p. 1–7.

22. Simpson JL, Grissell TV, Douwes J, Scott RJ, Boyle MJ, Gibson PG. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007; p. 211–218.

23. Green BJ, Wiriyachaiporn S, Grainge C, Rogers GB, Kehagia V, Lau L, Carroll MP, Bruce KD, Howarth PH. Potentially Pathogenic Airway Bacteria and Neutrophilic Inflammation in Treatment-Resistant Severe Asthma. PLoS ONE 2014; p. e100645.

24. Denlinger LC, Phillips BR, Ramratnam S, Ross K, Bhakta NR, Cardet JC, Castro M, Peters SP, Phipatanakul W, Aujla S, Bacharier LB, Bleecker ER, Comhair SAA, Coverstone A, DeBoer M, Erzurum SC, Fain SB, Fajt M, Fitzpatrick AM, Gaffin J, Gaston B, Hastie AT, Hawkins GA, Holguin F, Irani A-M, Israel E, Levy BD, Ly N, Meyers DA, Moore WC, et al. Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations. Am. J. Respir. Crit. Care Med. 2017; 195: 302–313.

25. Lemière C, Boulet L-P, Chaboillez S, Forget A, Chiry S, Villeneuve H, Prince P, Maghnii K, Kennedy WA, Blais L. Work-exacerbated asthma and occupational asthma: Do they really differ? J. Allergy Clin. Immunol. 2013; p.
26. Dominguez-Ortega J, Barranco P, Rodríguez-Pérez R, Quirce S. Biomarkers in Occupational Asthma. *Curr. Allergy Asthma Rep.* 2016; 16: 63.

27. Schleich FN, Seidel L, Sele J, Manise M, Quaedvlieg V, Michils A, Louis R. Exhaled nitric oxide thresholds associated with a sputum eosinophil count $\geq$3% in a cohort of unselected patients with asthma. Thorax 2010. p. 1039–1044.

28. Belda J, Leigh R, Parameswaran K, O’byrne PM, Sears MR, Hargreave FE. Induced Sputum Cell Counts in Healthy Adults. American Journal of Respiratory and Critical Care Medicine 2000. p. 475–478.

29. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: Assessment and identification using induced sputum. Respirology 2006. p. 54–61.

30. Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulmonary Medicine 2013.

31. Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, Wenzel SE, Peters SP, Meyers DA, Bleecker ER. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. Journal of Allergy and Clinical Immunology 2014. p. 1557–1563.e5.

32. Wang H, Dasgupta A, Lee K-A, Cook RJ, Nair P. Changing Pattern of Sputum Cell Counts During Successive Exacerbations of Chronic Obstructive Pulmonary Disease. *COPD* 2015; 12: 628–635.

33. Arron JR, Choy DF, Laviolette M, Kelsen SG, Hatab A, Leigh R, Thomson NC, Bleecker ER, Olivenstein R, Avila PC, Jarjour NN, Castro M, Gauvreau GM, Good JT, Kline JN, Mansur A, Mayers I, Heaney LG, Hamid Q, Harris JM. Disconnect between sputum neutrophils and other measures of airway inflammation in asthma. European Respiratory Journal 2014. p. 627–629.
34. Berry M, Morgan A, Shaw DE, Parker D, Green R, Brightling C, Bradding P, Wardlaw AJ, Pavord ID. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007. p. 1043–1049.

35. Nair P, Aziz-Ur-Rehman A, Radford K. Therapeutic implications of "neutrophilic asthma". Current Opinion in Pulmonary Medicine 2015. p. 33–38.

36. Peters MC, McGrath KW, Hawkins GA, Hastie AT, Levy BD, Israel E, Phillips BR, Mauger DT, Comhair SA, Erzurum SC, Johansson MW, Jarjour NN, Coverstone AM, Castro M, Holguin F, Wenzel SE, Woodruff PG, Bleecker ER, Fahy JV, National Heart, Lung, and Blood Institute Severe Asthma Research Program. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med 2016; 4: 574–584.

37. Ntontsi P, Loukides S, Bakakos P, Kostikas K, Papantheodorou G, Papanthanassiou E, Hillas G, Koulouris N, Papiris S, Papaioannou Al. Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: Comparison with different sputum phenotypes. Allergy 2017. p. 1761–1767.

38. Gibson PG, Simpson JL, Saltos N. Heterogeneity of Airway Inflammation in Persistent Asthma. Chest 2001. p. 1329–1336.

39. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic Inflammation in Severe Persistent Asthma. American Journal of Respiratory and Critical Care Medicine 1999. p. 1532–1539.

40. Silvestri M, Bontempelli M, Giacomelli M, Malerba M, Rossi GA, Di Stefano A, Rossi A, Ricciardolo FLM. High serum levels of tumour necrosis factor-? and interleukin-8 in severe asthma: markers of systemic inflammation?. Clinical & Experimental Allergy 2006. p. 1373–1381.

41. Casale TB. Biologics and biomarkers for asthma, urticaria, and nasal polyposis. J. Allergy Clin. Immunol. 2017; 139: 1411–1421.
42. Al-Ramli W, Préfontaine D, Chouiali F, Martin JG, Olivenstein R, Lemière C, Hamid Q. TH17-associated cytokines (IL-17A and IL-17F) in severe asthma. Journal of Allergy and Clinical Immunology 2009. p. 1185–1187.

43. Maes T, Cobos FA, Schleich F, Sorbello V, Henket M, De Preter K, Bracke KR, Conickx G, Mesnil C, Vandesompele J, Lahousse L, Bureau F, Mestdagh P, Joos GF, Ricciardolo FLM, Brusselle GG, Louis R. Asthma inflammatory phenotypes show differential microRNA expression in sputum. J. Allergy Clin. Immunol. 2016; 137: 1433–1446.

44. Singhania A, Wallington JC, Smith CG, Horowitz D, Staples KJ, Howarth PH, Gadola SD, Djukanović R, Woelk CH, Hinks TSC. Multitissue Transcriptomics Delineates the Diversity of Airway T Cell Functions in Asthma. Am. J. Respir. Cell Mol. Biol. 2018; 58: 261–270.

45. Research CM, Case Medical Research. Microbiome and Exacerbations in Neutrophilic Asthma. Case Medical Research 2020.

46. Simpson JL, Daly J, Baines KJ, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Hugenholtz P, Willner D, Gibson PG. Airway dysbiosis: Haemophilus influenzae and Tropheryma in poorly controlled asthma. Eur. Respir. J. 2016; 47: 792–800.

47. De Schutter I, Dreesman A, Soetens O, De Waele M, Crokaert F, Verhaegen J, Piérard D, Malfroot A. In young children, persistent wheezing is associated with bronchial bacterial infection: a retrospective analysis. BMC Pediatr. 2012; 12: 83.

48. Hynes GM, Hinks TSC. The role of interleukin-17 in asthma: a protective response?. ERJ Open Research 2020. p. 00364–02019.

49. Chaudhuri R, McSharry C, Brady J, Donnelly I, Grierson C, McGuinness S, Jolly L, Weir CJ, Messow CM, Spears M, Miele G, Nocka K, Crowther D, Thompson J, Brannigan M, Lafferty J, Sproule M, Macnee W, Connell M, Murchison JT, Shepherd MC, Feuerstein G, Miller DK, Thomson NC. Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary
50. Mukhopadhyay S, Sypek J, Tavendale R, Gartner U, Winter J, Li W, Page K, Fleming M, Brady J, O'Toole M, Macgregor DF, Goldman S, Tam S, Abraham W, Williams C, Miller DK, Palmer CNA. Matrix metalloproteinase-12 is a therapeutic target for asthma in children and young adults. J. Allergy Clin. Immunol. 2010; 132: 70–76.e16.

51. Hunninghake GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila L, Lasky-Su J, Stidley C, Melén E, Söderhäll C, Hallberg J, Kull I, Kere J, Svartengren M, Pershagen G, Wickman M, Lange C, Demeo DL, Hersh CP, Klanderman BJ, Raby BA, Sparrow D, Shapiro SD, Silverman EK, Litonjua AA, Weiss ST, Celedón JC. MMP12, lung function, and COPD in high-risk populations. N. Engl. J. Med. 2009; 361: 2599–2608.

52. Cooper PR, Mesaros AC, Zhang J, Christmas P, Stark CM, Douaidy K, Mittelman MA, Soberman RJ, Blair IA, Panettieri RA. 20-HETE mediates ozone-induced, neutrophil-independent airway hyper-responsiveness in mice. PLoS One 2010; 5: e10235.

53. Chaudhuri R, Livingston E, McMahon AD, Lafferty J, Fraser I, Spears M, McSharry CP, Thomson NC. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am. J. Respir. Crit. Care Med. 2006; 174: 127–133.

54. Kerstjens HAM, Disse B, Schröder-Babo W, Bantje TA, Gahlemann M, Sigmund R, Engel M, van Noord JA. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J. Allergy Clin. Immunol. 2011; 128: 308–314.

55. Lazarus SC, Krishnan JA, King TS, Lang JE, Blake KV, Covar R, Lugogo N, Wenzel S, Chinchilli VM, Mauger DT, Dyer A-M, Boushey HA, Fahy JV, Woodruff PG, Bacharier LB, Cabana MD, Cardet JC, Castro M, Chmiel J, Denlinger L, DiMango E, Fitzpatrick AM, Gentile D, Hastie A, Holguin F, Israel E, Jackson D, Kraft M, LaForce C, Lemanske RF Jr, et al. Mometasone or
Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. *N. Engl. J. Med.* 2019; 380: 2009–2019.

56. Cameron EJ, McSharry C, Chaudhuri R, Farrow S, Thomson NC. Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. *Clin. Exp. Allergy* 2012; 42: 1302–1312.

57. Jelić D, Antolović R. From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials. *Antibiotics (Basel)* 2016; 5.

58. Schögler A, Kopf BS, Edwards MR, Johnston SL, Casaulta C, Kieninger E, Jung A, Moeller A, Geiser T, Regamey N, Alves MP. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. *Eur. Respir. J.* 2015; 45: 428–439.

59. Kobayashi Y, Wada H, Rossios C, Takagi D, Charron C, Barnes PJ, Ito K. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. British Journal of Pharmacology 2013. p. 1024–1034.

60. Culić O, Eraković V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. *Eur. J. Pharmacol.* 2001; 429: 209–229.

61. Azithromycin for Prevention of Exacerbations of COPD. New England Journal of Medicine 2011. p. 2234–2237.

62. Amarasiri DL, Pathmeswaran A, de Silva HJ, Ranasinha CD. Response of the airways and autonomic nervous system to acid perfusion of the esophagus in patients with asthma: a laboratory study. *BMC Pulm. Med.* 2013; 13: 33.

63. Ribó P, Pacheco A, Arrieta P, Teruel C, Cobeta I. Gastroesophageal reflux as a cause of chronic cough, severe asthma, and migratory pulmonary infiltrates. Respirology Case Reports 2014. p. 1–3.

64. Tomomasa T, Kuroume T, Arai H, Wakabayashi K, Itoh Z. Erythromycin induces migrating motor complex in human gastrointestinal tract. *Dig. Dis. Sci.* 1986; 31: 157–161.
65. Pennathur A, Tran A, Cioppi M, Fayad J, Sieren GL, Little AG. Erythromycin strengthens the defective lower esophageal sphincter in patients with gastroesophageal reflux disease. *Am. J. Surg.* 1994; 167: 169–172; discussion 172–173.

66. Catnach SM, Fairclough PD. Erythromycin and the gut. *Gut* 1992; 33: 397–401.

67. Broad J, Sanger GJ. The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. *Br. J. Pharmacol.* 2013; 168: 1859–1867.

68. Sifrim D, Matsuo H, Janssens J, Vantrappen G. Comparison of the effects of midecamycin acetate and azithromycin on gastrointestinal motility in man. *Drugs Exp. Clin. Res.* 1994; 20: 121–126.

69. Essilfie A-T, Horvat JC, Kim RY, Mayall JR, Pinkerton JW, Beckett EL, Starkey MR, Simpson JL, Foster PS, Gibson PG, Hansbro PM. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. *Thorax* 2015; 70: 458–467.

70. Cameron EJ, Chaudhuri R, Mair F, McSharry C, Greenlaw N, Weir CJ, Jolly L, Donnelly I, Gallacher K, Morrison D, Spears M, Evans TJ, Anderson K, Thomson NC. Randomised controlled trial of azithromycin in smokers with asthma. *Eur. Respir. J.* 2013; 42: 1412–1415.

71. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, Marks GB, Baraket M, Powell H, Taylor SL, Leong LEX, Rogers GB, Simpson JL. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. *Lancet* 2017; 390: 659–668.

72. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. *Am. J. Respir. Crit. Care Med.* 2008; 177: 148–155.

73. Chung KF, Wenzel SE, Brozek JL, for the ERS/ATS Task Force on Definition,
Evaluation and Treatment of Severe Asthma. Comment on: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal 2014. p. 267–268.

74. Ong KY. What's new in the Global Initiative for Asthma 2018 report and beyond. Allergo Journal International 2019. p. 63–72.

75. Laxmanan B, Egressy K, Murgu SD, White SR, Hogarth DK. Advances in Bronchial Thermoplasty. Chest 2016; 150: 694–704.

76. Schuhmann M, Konietzke P, Wielpütz M, Weinheimer O, Kaukel P, Eberhardt R, Herth FJF, Heussel CP. Reduction of bronchial wall thickness and hyperinflation on quantitative CT after bronchial thermoplasty for severe asthma. Interventional Pulmonology 2017.

77. Thomson NC. Novel approaches to the management of noneosinophilic asthma. Therapeutic Advances in Respiratory Disease 2016. p. 211–234.

78. Ulrik CS. Asthma and obesity: is weight reduction the key to achieve asthma control? Curr. Opin. Pulm. Med. 2016; 22: 69–73.

79. Adeniyi FB, Young T. Weight loss interventions for chronic asthma. Cochrane Database Syst. Rev. 2012; : CD009339.

80. Forno E, Han Y-Y, Mullen J, Celedón JC. Overweight, Obesity, and Lung Function in Children and Adults—A Meta-analysis. The Journal of Allergy and Clinical Immunology: In Practice 2018; 6: 570–581.e10.

81. Zhu L, Ciaccio CE, Casale TB. Potential new targets for drug development in severe asthma. World Allergy Organ. J. 2018; 11: 30.

82. Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003; 284: L566–L577.

83. Xu X, Jackson PL, Tanner S, Hardison MT, Abdul Roda M, Blalock JE, Gaggar A. A self-propagating matrix metalloprotease-9 (MMP-9) dependent cycle of chronic neutrophilic inflammation. PLoS One 2011; 6: e15781.
84. Traves SL, Culpitt SV, Russell REK, Barnes PJ, Donnelly LE. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. *Thorax* 2002; 57: 590–595.

85. Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O'Byrne PM, Stryzak P, Gann L, Sadeh J, Chanez P, Study Investigators. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. *Clin. Exp. Allergy* 2012; 42: 1097–1103.

86. O'Byrne PM, Metev H, Puu M, Richter K, Keen C, Uddin M, Larsson B, Cullberg M, Nair P. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine 2016. p. 797–806.

87. Leaker BR, Barnes PJ, O'Connor B. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. *Respir. Res.* 2013; 14: 137.

88. Sergejeva S, Ivanov S, Lötvall J, Lindén A. Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway inflammation. *Am. J. Respir. Cell Mol. Biol.* 2005; 33: 248–253.

89. Fogli LK, Sundrud MS, Goel S, Bajwa S, Jensen K, Derudder E, Sun A, Coffre M, Uyttenhove C, Van Snick J, Schmidt-Supprian M, Rao A, Grunig G, Durbin J, Casola SS, Rajewsky K, Korolov SB. Correction: T cell–derived IL-17 mediates epithelial changes in the airway and drives pulmonary neutrophilia. The Journal of Immunology 2013. p. 5318–5318.

90. Ricciardolo FLM, Sorbello V, Vallese D, Massaglia GM, Favatà G, Di Stefano A. Expression of nasal and bronchial IL-17F and related cytokines in frequent exacerbators with neutrophilic severe asthma. 5.2 Monitoring Airway Disease 2016.

91. Chen R, Zhang Q, Chen S, Tang H, Huang P, Wei S, Liang Z, Chen X, Tao A, Yao L. IL-17F, rather than IL-17A, underlies airway inflammation in a steroid-
insensitive toluene diisocyanate-induced asthma model. *Eur. Respir. J.* 2019; 53.

92. Zhang M, Fei X, Zhang G-Q, Zhang P-Y, Li F, Bao W-P, Zhang Y-Y, Zhou X. Role of neutralizing anti-murine interleukin-17A monoclonal antibody on chronic ozone-induced airway inflammation in mice. Biomedicine & Pharmacotherapy 2016. p. 247–256.

93. Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, Lin S-L. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. *Am. J. Respir. Crit. Care Med.* 2013; 188: 1294–1302.

94. Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma - Full Text View - ClinicalTrials.gov.Available from: https://clinicaltrials.gov/ct2/show/NCT03299686.

95. Miller M. Phosphodiesterase inhibition in the treatment of autoimmune and inflammatory diseases: current status and potential. Journal of Receptor, Ligand and Channel Research 2014. p. 19. Available from: http://dx.doi.org/10.2147/jrlcr.s50401.

96. Verona Pharma reports positive results from RPL554 dose-finding study - Verona Pharma. Verona Pharma.Available from: https://www.veronapharma.com/media/verona-pharma-reports-positive-results-rpl554-dose-finding-study.

97. Singh D, Abbott-Banner K, Bengtsson T, Newman K. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. European Respiratory Journal 2018. p. 1801074.

98. Lucci G, Mariotti F, Santoro D, Acerbi D, Poli G, Nandeuil M-A. Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers. *Eur. Respir. J.* European Respiratory Society; 2016.
99. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén S-E, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P, T03 Asthma Investigators. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. *Am. J. Respir. Crit. Care Med.* 2009; 179: 549–558.

100. Antoniu SA. Cytokine antagonists for the treatment of asthma: progress to date. *BioDrugs* 2009; 23: 241–251.

101. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, Barnes PJ, Hansel TT. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. *Am. J. Respir. Crit. Care Med.* 2006; 174: 753–762.

102. He Y, Peng S, Xiong W, Xu Y, Liu J. Association between polymorphism of interleukin-1 beta and interleukin-1 receptor antagonist gene and asthma risk: a meta-analysis. *ScientificWorldJournal* 2015; 2015: 685684.

103. Konno S, Gonokami Y, Kurokawa M, Kawazu K, Asano K, Okamoto K, Adachi M. Cytokine concentrations in sputum of asthmatic patients. *Int. Arch. Allergy Immunol.* 1996; 109: 73–78.

104. Mazzarella G, Grella E, D’Auria D, Paciocco G, Perna F, Petillo O, Peluso G. Phenotypic features of alveolar monocytes/macrophages and IL-8 gene activation by IL-1 and TNF-alpha in asthmatic patients. *Allergy* 2000; 55 Suppl 61: 36–41.

105. Sousa AR, Lane SJ, Nakhosteen JA, Lee TH, Poston RN. Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. *Am. J. Respir. Crit. Care Med.* 1996; 154: 1061–1066.

106. Hernandez ML, Wagner JG, Kala A, Mills K, Wells HB, Alexis NE, Lay JC, Jiang Q, Zhang H, Zhou H, Peden DB. Vitamin E, γ-tocopherol, reduces airway neutrophil recruitment after inhaled endotoxin challenge in rats and in
healthy volunteers. *Free Radic. Biol. Med.* 2013; 60: 56–62.

107. Kim RY, Pinkerton JW, Essilfie AT, Robertson AAB, Baines KJ, Brown AC, Mayall JR, Khadem Ali M, Starkey MR, Hansbro NG, Hirota JA, Wood LG, Simpson JL, Knight DA, Wark PA, Gibson PG, O'Neill LAJ, Cooper MA, Horvat JC, Hansbro PM. Role for NLRP3 Inflammasome–mediated, IL-1β–Dependent Responses in Severe, Steroid-Resistant Asthma. *American Journal of Respiratory and Critical Care Medicine* 2017. p. 283–297.

108. Church LD, McDermott MF. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes. *Expert Rev. Clin. Immunol.* 2010; 6: 831–841.

109. Hernandez ML, Mills K, Almond M, Todoric K, Aleman MM, Zhang H, Zhou H, Peden DB. IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers. *J. Allergy Clin. Immunol.* 2015; 135: 379–385.

110. Chu DK, Al-Garawi A, Llop-Guevara A, Pillai RA, Radford K, Shen P, Walker TD, Goncharova S, Calhoun WJ, Nair P, Jordana M. Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma. *Allergy Asthma Clin. Immunol.* 2015; 11: 14.

111. Banno A, Reddy AT, Lakshmi SP, Reddy RC. PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma. Nuclear Receptor Research 2018.

112. A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma. ClinicalTrials.gov Identifier: NCT02794519. Available from: ClinicalTrials.gov Identifier: NCT02794519.

113. Lea S, Harbron C, Khan N, Booth G, Armstrong J, Singh D. Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor. *British Journal of Clinical Pharmacology* 2015. p. 756–766.

114. An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled
Asthma. Available from: clinicaltrials.gov/ct2/show/NCT02219048.

115. Marks-Konczalik J, Costa M, Robertson J, McKie E, Yang S, Pascoe S. A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils. Respiratory Medicine 2015. p. 860–869.

116. Patel NR, Cunoosamy DM, Fagerås M, Taib Z, Asimus S, Hegelund-Myrbäck T, Lundin S, Pardali K, Kurian N, Ersdal E, Kristensson C, Korsback K, Palmér R, Brown MN, Greenaway S, Siew L, Clarke GW, Rennard SI, Make BJ, Wise RA, Jansson P. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 1009–1019.

117. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur. J. Pharmacol. 2006; 533: 327–340.

118. Humbert M, de Blay F, Garcia G, Prud'homme A, Leroyer C, Magnan A, Tunon-de-Lara J-M, Pison C, Aubier M, Charpin D, Vachier I, Purohit A, Gineste P, Bader T, Moussy A, Hermine O, Chanez P. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. 2009; 64: 1194–1201.

119. Khindri S, Cahn A, Begg M, Montembault M, Leemereise C, Cui Y, Hogg A, Wajdner H, Yang S, Robertson J, Hamblin JN, Ludwig-Sengpiel A, Kornmann O, Hessel EM. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma. J. Pharmacol. Exp. Ther. 2018; 367: 405–413.

120. Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li L-S, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and
suppresses activity in autoimmune and inflammatory disease models. *Chem. Biol.* 2013; 20: 1364–1374.

121. Doukas J, Eide L, Stebbins K, Racanelli-Layton A, Dellamary L, Martin M, Dneprovskaiia E, Noronha G, Soll R, Wrasidlo W, Acevedo LM, Cheresh DA. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. *J. Pharmacol. Exp. Ther.* 2009; 328: 758–765.

122. Koziol-White CJ, Zhang J, Yoo E, Charron C, Stevenson C, Panettieri RA. A Narrow Spectrum Kinase Inhibitor, RV1729, Induces Bronchodilation of Human Small Airways and Rescues Agonist-Induced Desensitization of the 2 Adrenoreceptor (2AR). A29. INFLAMMATION AND MECHANISMS OF AIRWAY SMOOTH MUSCLE CONTRACTION American Thoracic Society; 2016. p. A1260–A1260.

123. Southworth T, Plumb J, Gupta V, Pearson J, Ramis I, Lehner MD, Miralpeix M, Singh D. Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients. *Respir. Res.* 2016; 17: 124.

124. Zhang L-B, He M. Effect of mesenchymal stromal (stem) cell (MSC) transplantation in asthmatic animal models: A systematic review and meta-analysis. *Pulm. Pharmacol. Ther.* 2019; 54: 39–52.

125. Yoo EJ, Ojiaku CA, Sunder K, Panettieri RA Jr. Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches. *Am. J. Respir. Cell Mol. Biol.* 2017; 56: 700–707.
Figure 1: T2-low asthma pathways and potential therapeutic targets